Pfizer Pharma - Search News

Haleon, Pfizer

Pfizer to sell $3 billion stake in Sensodyne maker Haleon

Pfizer is looking to sell about 700 million ordinary shares in Haleon , its bookrunner J.P. Morgan said on Tuesday, lowering its stake in the British consumer healthcare company to about 7.3% from 15%.

Hosted on MSN · 4d

Why Pfizer sold its $3 billion stake in Haleon

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,

Wall Street Journal · 4d

Pfizer Sells 700 Million Haleon Shares for $3.05 Billion

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

MarketWatch · 4d

Pfizer Has Sold 700M Haleon Shares

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top

Hosted on MSN1d

Pfizer believes in the metaverse: will healthcare thaw the technology’s winter?

The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.

5d

Pfizer going 'all in' on obesity drug development, CEO Bourla says

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

1d

EU ‘declares war’ on toxic chemicals: why big pharma and IT giants could flee Ireland for the US

The US could be the beneficiary of a potential blanket ban on the use of PFAS, better known as ‘forever chemicals’.

Pharmaceutical companies spike EpiPen prices 600% while allegedly deceiving Hoosier consumers

Attorney General Todd Rokita has filed a lawsuit alleging that Mylan and Pfizer have conspired to increase EpiPen’s price by ...

JPM25, Day 1: Pfizer CEO discusses plan to overcome $17B 'LOE wave'

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year. | For ...

Pharmaceutical Technology on MSN5d

Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Indiana's attorney general sues 2 pharmaceutical companies over EpiPen costs

The lawsuit filed Thursday in Marion County Superior Court accuses Mylan and Pfizer of conspiring to raise the price of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results